36
Participants
Start Date
November 1, 2016
Primary Completion Date
May 9, 2018
Study Completion Date
June 17, 2020
Durvalumab
Given IV
Laboratory Biomarker Analysis
Correlative Studies
Surgical Procedure
Undergo surgical tumor resection
Tremelimumab
Given IV
Northwestern University, Chicago
Collaborators (2)
AstraZeneca
INDUSTRY
MedImmune LLC
INDUSTRY
National Cancer Institute (NCI)
NIH
Northwestern University
OTHER